2025 Scrip Asia 100
Latest Updates And Considerations In Asia Pacific
China
China’s biopharma sector is pushing forward with significant innovations, particularly in oncology and biologics, though market pressures and regulatory hurdles continue to pose challenges for sustained growth.
Diversification Gains Momentum As Companies Look To Derisk China
Quietly but unambiguously, pharma firms are accelerating their diversification away from China and are now looking to other emerging markets for growth, a strategy that reflects increasing pressures from China's volume-based procurement scheme but also US-China tensions and other geopolitical risks.
